类风湿性关节炎患者间充质干细胞治疗后可溶性补体受体2的变化及意义

Change of soluble complement receptor 2 in the treatment of rheumatoid arthritis by umbilical cord mesenchymal stem cells

目的:探索类风湿性关节炎(RA)患者应用人脐带间充质干细胞(h UC-MSCs)治疗前后可溶性补体受体2(s CR2)的变化及意义。方法:体外培养h UC-MSCs,分别以终浓度为1×107个/50 ml静脉回输给40例RA患者,评价回输后的安全性和有效性,同时招募37名健康志愿者为对照组。采用酶联免疫吸附实验检测回输前后患者外周血s CR2的变化。结果:全部患者临床症状均有明显改善,且治疗前后血常规和肝肾功能检测无显著变化。RA患者血清s CR2水平明显低于健康对照组,经h UC-MSCs治疗后显著升高(13.07%vs 8.20%),与治疗前相比具有统计学意义(P<0.01)。结论:h UC-MSCs治疗可缓解RA患者的临床症状,且安全性良好,可能与上调s CR2表达有关。

Objective:To investigate the changes and significance of soluble complement receptor 2(s CR2) in the treatment of rheumatoid arthritis(RA) by human umbilical cord mesenchymal stem cells(h UC-MSCs). Methods:Primary h UC-MSCs were obtained from healthy puerpera and screened by the adhesive method,40 RA patients and 37 healthy controls were enrolled. A dose of 1 × 107 h UC-MSCs were transfused into 40 patients individually. Plasma levels of s CR2 were determined by enzyme-linked immunosorbent assay(ELISA) before and after treatment by h UC-MSCs.Results:All clinical parameters were improved after the treatment for all the patients. No significant difference was observed when comparing post-treatment with pre-treatment of biochemical parameters,including blood routine,hepatic function and renal function. Significantly lower level of serum s CR2 was found in RA patients compared with healthy controls. The serum s CR2 level in RA patients was increased significantly after h UC-MSCs treatment compared with before treatment(P < 0. 01). After h UC-MSCs therapy,the ratios were increased significantly in comparison with before treatment. Conclusion:The h UC-MSCs can relieve the clinical status for RA patients,which is a safe therapeutic method.The treatment outcome after h UC-MSCs transfusion for RA patients may be involved in the overexpression of s CR2.